$1.38 -0.05 (-3.50%)
12/3/2009 3:59 PM

Inovio Biomedical Corp. (INO)

CAPS Rating: 1 out of 5

A biomedical company which deals in developing human applications of electroporation, which uses brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceuticals.

Current Price $1.38 Mkt Cap $140.94M
Open $1.41 P/E Ratio 0.00
Prev. Close $1.43 Div. (Yield) N/A (N/A)
Daily Range $1.35 - $1.46 Volume 429,798
52-Wk Range $0.18 - $3.40 Avg. Daily Vol. 1,041,000

INO News and Commentary

Caps

This ticker is not currently Ratable.

Add Stock to Watchlist

All Members

56 Outperform
14 Underperform
 

All-Star Members

12 Outperform
10 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top INO Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

8tune (61.42)
Submitted July 31, 2009

INO is developing vacinnes against A/H1N1 and Dengue fever.

cecamadocv (97.94)
Submitted November 20, 2009

I think this company is a scam, everyday they have a press release of some bullsh*t.

Usually its we have a cure for aids, or we have the answer for world peace...

croc of shi* i tell you

INO VS S&P 500 (SPY)

Fools bullish on INO are also bullish on:

Fools bearish on INO are also bearish on:

Recent Community Commentary

Read the most recent pitches from members about INO.

Recs

0
Member Avatar zzlangerhans (99.57) Submitted: 11/20/2009 4:18:09 PM : Underperform Start Price: $1.52 INO Score: +10.39

The newfound value of Inovio follows from their merger with VGX and their DNA vaccine technology, and the fortuitous (for them) occurrence of the H1N1 epidemic. As long as this epidemic remains hot news, Inovio stock will shoot upward with the slightest hint of progress in their technology. Today's burst was due to more reprots about protective immunity in animal studies. In case you weren't reading closely, that's preclinical. Even Inovio CEO J. Joseph Kim admits in a street.com interview that the project is in early stages. "We're not going to have a product on the shelf this fall," he said. "But the power of our approach -- we're going to be there when these other traditional approaches fail." Maybe. But when this epidemic is history, so will be Inovio over 1. Fortunately the company took advantage of the initial irrational burst of dilution to cash in with a sweet dilutive financing which will keep them around for quite a while. Nice move on that merger, Inovio.

Recs

0
Member Avatar pfenix (< 20) Submitted: 11/20/2009 1:09:23 PM : Outperform Start Price: $1.53 INO Score: -10.88

flu vaccine not based on old outdated viruses...uses DNA to fight viruses naturally

Recs

0
Member Avatar usmcnoob (< 20) Submitted: 8/21/2009 7:12:59 PM : Outperform Start Price: $2.02 INO Score: -38.95

Once they get FDA approval, this stock should soar. Just hope that they get FDA approval...

Leaderboard

Find the members with the highest scoring picks in INO.

Score Leader

4everlost

4everlost (95.38) Score: +55.17

The Score Leader is the member with the highest score across all their picks in INO.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
4everlost 95.38 8/5/2009 Underperform 1Y $2.51 -45.04% +10.13% +55.17
BicaChica 81.66 8/3/2009 Underperform 5Y $2.36 -41.53% +11.04% +52.57
Longorshort25 74.69 8/6/2009 Underperform 5Y $2.34 -41.03% +10.95% +51.97
epc53 99.28 7/31/2009 Underperform 5Y $2.12 -34.91% +11.82% +46.73
abitare 99.59 7/31/2009 Underperform 1Y $2.09 -33.97% +12.24% +46.21
virtuexru 53.66 7/30/2009 Underperform 5Y $2.09 -33.97% +11.72% +45.70
rhinomaj 87.50 8/4/2009 Underperform 3M $2.09 -33.97% +10.50% +44.47
HunterNumber9 57.50 10/5/2009 Underperform 5Y $1.83 -24.59% +7.27% +31.86
Kierraquick 95.91 11/23/2009 Underperform NS $1.66 -16.87% -0.31% +16.56
guru111melbourne < 20 11/24/2009 Underperform 5Y $1.55 -10.97% -0.56% +10.41

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackTWeisel < 20 4/25/2007 Outperform NS $3.90 -64.62% -21.54% -43.08

Featured Broker Partners